Abstract:The last step in influenza virus replication involves the assembly of viral components on the infected cell's plasma membrane followed by budding of intact virus from the host cell surface. Because viral neuraminidase and hemagglutinin are both inserted into the host cell's membrane during this process, influenza virus-infected cells are distinguished from uninfected cells by the presence of viral neuraminidase and hemagglutinin on their cell surfaces. In an effort to exploit this difference in cell surface markers for development of diagnostic and therapeutic agents, we have modified an influenza neuraminidase inhibitor, zanamivir, for targeting of attached imaging and therapeutic agents selectively to influenza viruses and virus-infected cells. We have designed here a zanamivir-conjugated rhodamine dye that allows visual monitoring of binding, internalization, and intracellular trafficking of the fluorescence-labeled neuraminidase in virus-infected cells. We also synthesize a zanamivir-<sup>99m</sup>Tc radioimaging conjugate that permits whole body imaging of the virus's biodistribution and abundance in infected mice. Finally, we create both a zanamivir-targeted cytotoxic drug (i.e., zanamivir-tubulysin B) and a viral neuraminidase-targeted CAR T cell and demonstrate that they are both able to kill viral neuraminidase-expressing cells without damaging healthy cells. Taken together, these data suggest that the influenza virus neuraminidase inhibitor, zanamivir, can be exploited to improve the diagnosis, imaging, and treatment of influenza virus infections.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.bioconjchem.1c00255?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00255</a>.Experimental details, materials, and methods, including the spectra of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.bioconjchem.1c00255/suppl_file/bc1c00255_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Covalent Organic Framework-Based Theranostic Platforms for Restricting H1N1 Influenza Virus Infection

Influenza Virus Detection Technology Based on Organic Electrochemical Transistor

Sialylglycan-Assembled Supra-Dots for Ratiometric Probing and Blocking of Human-Infecting Influenza Viruses

Polylevodopa Nanoplatform for Lateral Flow Immunochromatography Assay of SARS-CoV-2 and Influenza A Virus

Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections

Sensitive and rapid detection of influenza A virus for disease surveillance using dual-probe electrochemical biosensor

Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 Therapy.

Development of Broad-spectrum β-cyclodextrins-Based Nanomaterials Against Influenza Viruses

Bleomycin-Fe(II) agent with potentiality for treating drug-resistant H1N1 influenza virus: A study using electrochemical RNA beacons

Anti-Influenza Virus Study of Composite Material with MIL-101(Fe)-Adsorbed Favipiravir

Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections

Residue-based Design of Small Molecule Inhibitor for H1N1, H5N1 and H7N1 Mutants

HCR-Assisted RTF-EXPAR-Based Lateral Flow Analysis for Sensitive Detection of H1N1 Influenza Virus

The Hybrid of Cu─TCPP@Mn3O4 for Inflammation Relief by ROS Scavenging and O2 Production: An Efficient Strategy for Antiviral Therapy

Identification of influenza A nucleoprotein as an antiviral target

Ligand-based Dual Target Drug Design for H1N1: Swine Flu--a Preliminary First Study.

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Modular Biomimetic Strategy Enables Discovery and SAR Exploration of Oxime Macrocycles as Influenza A Virus (H1N1) Inhibitors

Molecular Dynamics Analysis of Potent Inhibitors of M2 Proton Channel Against H1N1 Swine Influenza Virus

Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains

Proteomic Analysis at the Subcellular Level for Host Targets Against Influenza A Virus (H1N1)